Although one of the kinases inhibited by pacritinib, JAK2, has been implicated in the onset of GVHD and clinical trials of ruxolitinib to treat and prevent GVHD are underway, suppression of IRAK1 may also be an operative mechanism. Here, IRAK1 is linked to graft versus host disease.